<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262028</url>
  </required_header>
  <id_info>
    <org_study_id>V59P8</org_study_id>
    <nct_id>NCT00262028</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children</brief_title>
  <official_title>A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly
      Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10
      years
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine</measure>
    <time_frame>1 month post vaccination (Day 29)</time_frame>
    <description>Number of subjects (2-10 years of age) achieving with hSBA titers ≥1:4 against Neisseria meningitidis serogroups A,C,W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (2-5 Years of Age and 6-10 Years of Age) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine</measure>
    <time_frame>1 month post vaccination (Day 29)</time_frame>
    <description>Percentages of subjects (2-5 years of age and 6-10 years of age) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects (12-23 Months Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-CRM Vaccine Compared With Percentage of Subjects (3-5 Years Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-PS Vaccine</measure>
    <time_frame>1 month post vaccination (Day 29)</time_frame>
    <description>Percentage of subjects (12-23 months old) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y after receiving one dose of MenACWY-CRM vaccine compared with percentage of subjects (3-5 years old) with hSBA ≥ 1:4 after one dose of licensed MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years of Age) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</measure>
    <time_frame>1 month post vaccination (Day 29)</time_frame>
    <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-10 years of age), one month after receiving one dose of either MenACWY-CRM vaccine or the licensed MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA GMT in Subjects (2-5 Years of Age and 6-10 Years of Age) Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</measure>
    <time_frame>1 month post vaccination (Day 29)</time_frame>
    <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-5 years of age and 6-10 years of age), one month after receiving one dose of either MenACWY-CRM vaccine or licensed MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titer (GMT) in Subjects (12-23 Months Old) After Receiving MenACWY-CRM Vaccine Compared With hSBA GMT in 3-5 Year Old Subjects After Receiving MenACWY-PS Vaccine</measure>
    <time_frame>1 month post vaccination (Day 29)</time_frame>
    <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (12-23 months old), one month after receiving one dose of MenACWY-CRM vaccine compared with hSBA GMT in 3-5 year old subjects after receiving one dose of licensed MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</measure>
    <time_frame>12 months post vaccination (Day 360)</time_frame>
    <description>Number of subjects (2-10 years, 2-5 years and 6-10 years old subjects) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y, 12 months after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</measure>
    <time_frame>12 months post vaccination (Day 360)</time_frame>
    <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-10 years, 2-5 years and 6-10 years old), twelve months after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Children Aged 2 to 10 Years</measure>
    <time_frame>Day 1 to 7 post vaccination</time_frame>
    <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine compared to the safety and tolerability of a single dose of licensed MenACWY-PS vaccine when administered to healthy children 2 to 10 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months</measure>
    <time_frame>Day 1 to 7 post vaccination</time_frame>
    <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine when administered in healthy toddlers (12-15 months old), alone or concomitantly with PnC and when administered in healthy toddlers (16-23 months old), alone or concomitantly with DTaP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events (AEs) After Vaccination in Children Aged 2 to 10 Years</measure>
    <time_frame>Day 1- Day 360 (throughout the study)</time_frame>
    <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine compared to the safety and tolerability of a single dose of licensed MenACWY-PS vaccine when administered to healthy children 2 to 10 years of age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months</measure>
    <time_frame>Day 1- Day 360 (Throughout the study)</time_frame>
    <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine when administered in healthy toddlers (12-15 months old), alone or concomitantly with PnC and when administered in healthy toddlers (16-23 months old), alone or concomitantly with DTaP.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">910</enrollment>
  <condition>Prevention of Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM (2-10 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM (12-23 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-PS (2-10 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received one dose of licensed comparator MenACWY polysaccharide (MenACWY-PS) vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM+PnC (12-15 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with PnC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM+DTaP (16-23 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received one dose of MenACWY-CRM vaccine alone or concomitantly with DTaP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM Vaccine</intervention_name>
    <arm_group_label>MenACWY-CRM (2-10 years)</arm_group_label>
    <arm_group_label>MenACWY-CRM (12-23 months)</arm_group_label>
    <arm_group_label>MenACWY-CRM+PnC (12-15 months)</arm_group_label>
    <arm_group_label>MenACWY-CRM+DTaP (16-23 months)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-PS Vaccine</intervention_name>
    <arm_group_label>MenACWY-PS (2-10 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group 1: Healthy children 2-10 years of age;

          -  Group 2: Healthy toddlers 12-23 months of age; who are up to date with age appropriate
             immunizations for diphtheria, tetanus, pertussis, polio, hepatitis B, Hemophilus
             influenzae type b, and pneumococcus.

        Exclusion Criteria:

          -  Group 1: Subjects with a previous or suspected disease caused by N. meningitidis; or
             previous immunization with a meningococcal vaccine or vaccine containing meningococcal
             antigen(s); Any serious acute, chronic or progressive disease.

          -  Group 2: Subjects with a previous or suspected disease caused by N. meningitidis or
             previous immunization with a meningococcal vaccine or vaccine containing meningococcal
             antigen(s); Any serious acute, chronic or progressive disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines &amp; Diagnostics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente Vaccine Study Center</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2005</study_first_submitted>
  <study_first_submitted_qc>December 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <results_first_submitted>August 30, 2013</results_first_submitted>
  <results_first_submitted_qc>January 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2016</results_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from a single center.</recruitment_details>
      <pre_assignment_details>All enrolled subjects participated in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY (2-5 Years Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-cross-reactive material (CRM) conjugate vaccine.</description>
        </group>
        <group group_id="P2">
          <title>MenACWY-PS (2-5 Years Old)</title>
          <description>Subjects received one dose of the licensed MenACWY-polysaccharide vaccine.</description>
        </group>
        <group group_id="P3">
          <title>MenACWY (6-10 Years Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="P4">
          <title>MenACWY-PS (6-10 Years Old)</title>
          <description>Subjects received one dose of the licensed MenACWY-polysaccharide vaccine.</description>
        </group>
        <group group_id="P5">
          <title>MenACWY (12-15 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="P6">
          <title>MenACWY+PnC (12-15 Months)</title>
          <description>Subjects received one dose of the MenACWY-CRM conjugate vaccine administered concomitantly with pneumococcal conjugate vaccine (PnC).</description>
        </group>
        <group group_id="P7">
          <title>MenACWY (16-23 Months)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="P8">
          <title>MenACWY+DTaP (16-23 Months)</title>
          <description>Subjects received one dose of the MenACWY-CRM conjugate vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis (DTaP) vaccine.</description>
        </group>
        <group group_id="P9">
          <title>MenACWY-PS (3-5 Years Old)</title>
          <description>Children aged 3 to 5 years receiving MenACWY- polysaccharide (PS) vaccine from the first part of the study (Menomune, not licensed in US in children under 2 years of age) were used as controls for the 12-23-months-old part two toddlers.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="157"/>
                <participants group_id="P4" count="157"/>
                <participants group_id="P5" count="74"/>
                <participants group_id="P6" count="73"/>
                <participants group_id="P7" count="71"/>
                <participants group_id="P8" count="73"/>
                <participants group_id="P9" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="126"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="134"/>
                <participants group_id="P5" count="62"/>
                <participants group_id="P6" count="60"/>
                <participants group_id="P7" count="59"/>
                <participants group_id="P8" count="55"/>
                <participants group_id="P9" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="18"/>
                <participants group_id="P9" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenACWY (2-5 Years Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="B2">
          <title>MenACWY-PS (2-5 Years Old)</title>
          <description>Subjects received one dose of the licensed MenACWY-polysaccharide vaccine.</description>
        </group>
        <group group_id="B3">
          <title>MenACWY (6-10 Years Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
        </group>
        <group group_id="B4">
          <title>MenACWY-PS (6-10 Years Old)</title>
          <description>Subjects received one dose of the licensed MenACWY-polysaccharide vaccine.</description>
        </group>
        <group group_id="B5">
          <title>MenACWY (12-15 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="B6">
          <title>MenACWY-PnC (12-15 Months Old)</title>
          <description>Subjects received one dose of the MenACWY-CRM conjugate vaccine administered concomitantly with pneumococcal conjugate vaccine.</description>
        </group>
        <group group_id="B7">
          <title>MenACWY (16-23 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="B8">
          <title>MenACWY+DTaP (16-23 Months Old)</title>
          <description>Subjects received one dose of the MenACWY-CRM conjugate vaccine administered concomitantly with DTaP vaccine.</description>
        </group>
        <group group_id="B9">
          <title>MenACWY+PS (3-5 YearsOld)</title>
          <description>Children aged 3 to 5 years receiving MenACWY-PS from the first part of the study (Menomune, not licensed in US in children under 2 years of age) were used as controls for the 12-23-months-old part two toddlers.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="157"/>
            <count group_id="B4" value="157"/>
            <count group_id="B5" value="74"/>
            <count group_id="B6" value="73"/>
            <count group_id="B7" value="71"/>
            <count group_id="B8" value="73"/>
            <count group_id="B9" value="100"/>
            <count group_id="B10" value="1010"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.2"/>
                    <measurement group_id="B2" value="3.3" spread="1.2"/>
                    <measurement group_id="B3" value="8.0" spread="1.5"/>
                    <measurement group_id="B4" value="8.0" spread="1.4"/>
                    <measurement group_id="B5" value="NA">Data are reported in a separate table</measurement>
                    <measurement group_id="B6" value="NA">Data are reported in a separate table</measurement>
                    <measurement group_id="B7" value="NA">Data are reported in a separate table</measurement>
                    <measurement group_id="B8" value="NA">Data are reported in a separate table</measurement>
                    <measurement group_id="B9" value="NA">Data are reported in a separate table</measurement>
                    <measurement group_id="B10" value="5.7" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B2" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B3" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B4" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B5" value="12.2" spread="0.5"/>
                    <measurement group_id="B6" value="12.2" spread="0.5"/>
                    <measurement group_id="B7" value="18.2" spread="1.3"/>
                    <measurement group_id="B8" value="18.2" spread="1.4"/>
                    <measurement group_id="B9" value="52.6" spread="11.4"/>
                    <measurement group_id="B10" value="24.7" spread="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="NA">Data are reported in a separate table</measurement>
                    <measurement group_id="B6" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B7" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B8" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B9" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B10" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B6" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B7" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B8" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B9" value="NA">reported in a separate table</measurement>
                    <measurement group_id="B10" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B2" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B3" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B4" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="31"/>
                    <measurement group_id="B8" value="36"/>
                    <measurement group_id="B9" value="51"/>
                    <measurement group_id="B10" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B2" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B3" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B4" value="NA">Data are reported in the previous table</measurement>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="44"/>
                    <measurement group_id="B7" value="40"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="49"/>
                    <measurement group_id="B10" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine</title>
        <description>Number of subjects (2-10 years of age) achieving with hSBA titers ≥1:4 against Neisseria meningitidis serogroups A,C,W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
        <time_frame>1 month post vaccination (Day 29)</time_frame>
        <population>Analysis was done on per protocol population i.e. all subjects who received one dose of vaccine and provided serum samples at the relevant time points (day 1, day 29 and day 360) and had no major protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-10 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-10 Years)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (2-10 Years of Age) With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine</title>
          <description>Number of subjects (2-10 years of age) achieving with hSBA titers ≥1:4 against Neisseria meningitidis serogroups A,C,W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population i.e. all subjects who received one dose of vaccine and provided serum samples at the relevant time points (day 1, day 29 and day 360) and had no major protocol deviation.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=280, 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29), N=280, 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232"/>
                    <measurement group_id="O2" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=279, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29), N=279, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=280, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29), N=280, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Noninferiority of immune responses of MenACWY-CRM to licensed comparator against serogroup A</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>MenACWY-CRM was considered to be noninferior to the licensed comparator if the lower limit (LL) of the 95% confidence intervals (CI) of the difference (MenACWY minus licensed comparator)in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; -10% against each serogroup</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29</ci_lower_limit>
            <ci_upper_limit>44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Noninferiority of immune responses of MenACWY-CRM to licensed comparator against serogroup C</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>MenACWY-CRM was considered to be noninferior to the licensed comparator if the lower LL of the 95% CI of the difference (MenACWY minus licensed comparator)in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; -10% against each serogroup</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Noninferiority of immune responses of MenACWY-CRM to licensed comparator against serogroup W</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>MenACWY-CRM was considered to be noninferior to the licensed comparator if the LL of the 95% CI of the difference (MenACWY minus licensed comparator)in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; -10% against each serogroup</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>No inferiority of immune responses of MenACWY-CRM to licensed comparator against serogroup Y</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>MenACWY-CRM was considered to be noninferior to the licensed comparator if the LL of the 95% CI of the difference (MenACWY minus licensed comparator)in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; -10% against each serogroup</non_inferiority_desc>
            <param_type>Vaccine group difference</param_type>
            <param_value>31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25</ci_lower_limit>
            <ci_upper_limit>38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of MenACWY-CRM to licensed comparator against serogroup A
MenACWY-CRM was considered to be superior to the licensed comparator if the LL of the 95% CI of the difference (MenACWY minus licensed comparator) in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; 0% against each serogroup</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine group difference</param_type>
            <param_value>37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29</ci_lower_limit>
            <ci_upper_limit>44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of MenACWY-CRM to licensed comparator against serogroup C
MenACWY-CRM was considered to be superior to the licensed comparator if the LL of the 95% CI of the difference (MenACWY minus licensed comparator) in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; 0% against each serogroup</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine group difference</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12</ci_lower_limit>
            <ci_upper_limit>26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of MenACWY-CRM to licensed comparator against serogroup W
MenACWY-CRM was considered to be superior to the licensed comparator if the LL of the 95% CI of the difference (MenACWY minus licensed comparator) in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; 0% against each serogroup</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine group difference</param_type>
            <param_value>23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17</ci_lower_limit>
            <ci_upper_limit>29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superiority of immune responses of MenACWY-CRM to licensed comparator against serogroup Y
MenACWY-CRM was considered to be superior to the licensed comparator if the LL of the 95% CI of the difference (MenACWY minus licensed comparator) in the percentage of the subjects with hSBA titer ≥ 1:4 at one month post vaccination was &gt; 0% against each serogroup</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Vaccine group difference</param_type>
            <param_value>31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>25</ci_lower_limit>
            <ci_upper_limit>38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (2-5 Years of Age and 6-10 Years of Age) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine</title>
        <description>Percentages of subjects (2-5 years of age and 6-10 years of age) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
        <time_frame>1 month post vaccination (Day 29)</time_frame>
        <population>Analysis was done on per protocol population. The total number of participants analyzed in the MenACWY-CRM (2-10 Years Old) group (282), is different respect with that reported in the Outcome Measure 1 (281). There, the largest number for each group across the 4 strains was reported (not all strains had a result from the lab-i.e. C strain).</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-5 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-5 Years Old)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (6-10 Years Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS (6-10 Years Old)</title>
            <description>Subjects received one dose of licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (2-5 Years of Age and 6-10 Years of Age) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM or MenACWY-PS Vaccine</title>
          <description>Percentages of subjects (2-5 years of age and 6-10 years of age) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y, one month after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population. The total number of participants analyzed in the MenACWY-CRM (2-10 Years Old) group (282), is different respect with that reported in the Outcome Measure 1 (281). There, the largest number for each group across the 4 strains was reported (not all strains had a result from the lab-i.e. C strain).</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=133,138,147,143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="3" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="O4" value="1" lower_limit="0.018" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29), N=133,138,147,143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="72" upper_limit="86"/>
                    <measurement group_id="O2" value="43" lower_limit="34" upper_limit="51"/>
                    <measurement group_id="O3" value="83" lower_limit="76" upper_limit="89"/>
                    <measurement group_id="O4" value="46" lower_limit="38" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1), N=135,138,146,145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="16" upper_limit="31"/>
                    <measurement group_id="O2" value="11" lower_limit="6" upper_limit="17"/>
                    <measurement group_id="O3" value="34" lower_limit="26" upper_limit="42"/>
                    <measurement group_id="O4" value="46" lower_limit="37" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29), N=135,138,146,145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="68" upper_limit="83"/>
                    <measurement group_id="O2" value="45" lower_limit="36" upper_limit="54"/>
                    <measurement group_id="O3" value="88" lower_limit="82" upper_limit="93"/>
                    <measurement group_id="O4" value="82" lower_limit="75" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=135,138,144,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="24" upper_limit="40"/>
                    <measurement group_id="O2" value="22" lower_limit="16" upper_limit="30"/>
                    <measurement group_id="O3" value="47" lower_limit="39" upper_limit="56"/>
                    <measurement group_id="O4" value="53" lower_limit="45" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29), N=135,138,144,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="84" upper_limit="95"/>
                    <measurement group_id="O2" value="55" lower_limit="46" upper_limit="64"/>
                    <measurement group_id="O3" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O4" value="88" lower_limit="81" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=134,138,146,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12" upper_limit="25"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="20"/>
                    <measurement group_id="O3" value="25" lower_limit="19" upper_limit="33"/>
                    <measurement group_id="O4" value="35" lower_limit="27" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29), N=134,138,146,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="80" upper_limit="92"/>
                    <measurement group_id="O2" value="49" lower_limit="40" upper_limit="57"/>
                    <measurement group_id="O3" value="95" lower_limit="89" upper_limit="98"/>
                    <measurement group_id="O4" value="69" lower_limit="61" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects (12-23 Months Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-CRM Vaccine Compared With Percentage of Subjects (3-5 Years Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-PS Vaccine</title>
        <description>Percentage of subjects (12-23 months old) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y after receiving one dose of MenACWY-CRM vaccine compared with percentage of subjects (3-5 years old) with hSBA ≥ 1:4 after one dose of licensed MenACWY-PS vaccine.</description>
        <time_frame>1 month post vaccination (Day 29)</time_frame>
        <population>Analysis was done on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (12-23 Months Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (3-5 Years Old)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine. This group was a subset of the licensed comparator (2-5 years old) cohort that received one dose of licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects (12-23 Months Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-CRM Vaccine Compared With Percentage of Subjects (3-5 Years Old) With hSBA Titer ≥ 1:4 After Receiving MenACWY-PS Vaccine</title>
          <description>Percentage of subjects (12-23 months old) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y after receiving one dose of MenACWY-CRM vaccine compared with percentage of subjects (3-5 years old) with hSBA ≥ 1:4 after one dose of licensed MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="76" upper_limit="86"/>
                    <measurement group_id="O2" value="51" lower_limit="40" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1), N=241,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="12" lower_limit="6" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29), N=241,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="86" upper_limit="94"/>
                    <measurement group_id="O2" value="42" lower_limit="32" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="O2" value="24" lower_limit="16" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="81" upper_limit="90"/>
                    <measurement group_id="O2" value="63" lower_limit="52" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=238,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="5"/>
                    <measurement group_id="O2" value="15" lower_limit="9" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29), N=238,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="58" upper_limit="70"/>
                    <measurement group_id="O2" value="51" lower_limit="40" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years of Age) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
        <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-10 years of age), one month after receiving one dose of either MenACWY-CRM vaccine or the licensed MenACWY-PS vaccine.</description>
        <time_frame>1 month post vaccination (Day 29)</time_frame>
        <population>Analysis was done on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-10 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-10 Years)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years of Age) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
          <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-10 years of age), one month after receiving one dose of either MenACWY-CRM vaccine or the licensed MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="283"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=280, 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" lower_limit="2.02" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.98" upper_limit="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29), N=280, 281</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="30" upper_limit="44"/>
                    <measurement group_id="O2" value="6.31" lower_limit="5.21" upper_limit="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" lower_limit="2.77" upper_limit="3.4"/>
                    <measurement group_id="O2" value="3.33" lower_limit="3.01" upper_limit="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="21" upper_limit="34"/>
                    <measurement group_id="O2" value="15" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=279, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.74" lower_limit="4.86" upper_limit="6.78"/>
                    <measurement group_id="O2" value="5.63" lower_limit="4.77" upper_limit="6.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29), N=279, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="50" upper_limit="71"/>
                    <measurement group_id="O2" value="14" lower_limit="12" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=280, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.32" lower_limit="2.95" upper_limit="3.73"/>
                    <measurement group_id="O2" value="3.34" lower_limit="2.97" upper_limit="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29), N=280, 282</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" lower_limit="44" upper_limit="66"/>
                    <measurement group_id="O2" value="11" lower_limit="9.29" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA GMT in Subjects (2-5 Years of Age and 6-10 Years of Age) Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
        <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-5 years of age and 6-10 years of age), one month after receiving one dose of either MenACWY-CRM vaccine or licensed MenACWY-PS vaccine.</description>
        <time_frame>1 month post vaccination (Day 29)</time_frame>
        <population>Analysis was done on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-5 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-5 Years Old)</title>
            <description>Subjects received one dose of the MenACWY-PS vaccine</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (6-10 Years Old)</title>
            <description>Subjects received one dose of MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS (6-10 Years Old)</title>
            <description>Subjects received one dose of MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA GMT in Subjects (2-5 Years of Age and 6-10 Years of Age) Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
          <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-5 years of age and 6-10 years of age), one month after receiving one dose of either MenACWY-CRM vaccine or licensed MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=133,138,147,143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" lower_limit="2" upper_limit="2.07"/>
                    <measurement group_id="O2" value="2" lower_limit="1.97" upper_limit="2.03"/>
                    <measurement group_id="O3" value="2.08" lower_limit="2.01" upper_limit="2.15"/>
                    <measurement group_id="O4" value="2.03" lower_limit="1.96" upper_limit="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29), N=133,138,147,143</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="22" upper_limit="37"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.49" upper_limit="7.5"/>
                    <measurement group_id="O3" value="45" lower_limit="34" upper_limit="60"/>
                    <measurement group_id="O4" value="6.84" lower_limit="5.17" upper_limit="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1), N=135,138,146,145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" lower_limit="2.52" upper_limit="3.13"/>
                    <measurement group_id="O2" value="2.38" lower_limit="2.14" upper_limit="2.65"/>
                    <measurement group_id="O3" value="3.33" lower_limit="2.84" upper_limit="3.9"/>
                    <measurement group_id="O4" value="4.58" lower_limit="3.91" upper_limit="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29), N=135,138,146,145</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="19"/>
                    <measurement group_id="O2" value="6.93" lower_limit="5.22" upper_limit="9.18"/>
                    <measurement group_id="O3" value="47" lower_limit="34" upper_limit="67"/>
                    <measurement group_id="O4" value="33" lower_limit="23" upper_limit="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=135,138,144,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" lower_limit="3.78" upper_limit="5.8"/>
                    <measurement group_id="O2" value="3.64" lower_limit="2.95" upper_limit="4.5"/>
                    <measurement group_id="O3" value="6.94" lower_limit="5.45" upper_limit="8.84"/>
                    <measurement group_id="O4" value="8.55" lower_limit="6.71" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29), N=135,138,144,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="34" upper_limit="56"/>
                    <measurement group_id="O2" value="7.84" lower_limit="6.12" upper_limit="10"/>
                    <measurement group_id="O3" value="80" lower_limit="65" upper_limit="99"/>
                    <measurement group_id="O4" value="24" lower_limit="20" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=134,138,146,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.61" upper_limit="3.44"/>
                    <measurement group_id="O2" value="2.57" lower_limit="2.24" upper_limit="2.95"/>
                    <measurement group_id="O3" value="3.65" lower_limit="3.03" upper_limit="4.38"/>
                    <measurement group_id="O4" value="4.3" lower_limit="3.58" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29), N=134,138,146,144</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="31" upper_limit="56"/>
                    <measurement group_id="O2" value="7.17" lower_limit="5.37" upper_limit="9.58"/>
                    <measurement group_id="O3" value="68" lower_limit="51" upper_limit="90"/>
                    <measurement group_id="O4" value="18" lower_limit="13" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titer (GMT) in Subjects (12-23 Months Old) After Receiving MenACWY-CRM Vaccine Compared With hSBA GMT in 3-5 Year Old Subjects After Receiving MenACWY-PS Vaccine</title>
        <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (12-23 months old), one month after receiving one dose of MenACWY-CRM vaccine compared with hSBA GMT in 3-5 year old subjects after receiving one dose of licensed MenACWY-PS vaccine.</description>
        <time_frame>1 month post vaccination (Day 29)</time_frame>
        <population>Analysis was done on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (12-23 Months Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (3-5 Years Old)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine This group was a subset of the Licensed comparator (2-5 year old) cohort that received one dose of licensed MenACWY-PS vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titer (GMT) in Subjects (12-23 Months Old) After Receiving MenACWY-CRM Vaccine Compared With hSBA GMT in 3-5 Year Old Subjects After Receiving MenACWY-PS Vaccine</title>
          <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (12-23 months old), one month after receiving one dose of MenACWY-CRM vaccine compared with hSBA GMT in 3-5 year old subjects after receiving one dose of licensed MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="2" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 29), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="7.18" lower_limit="5.34" upper_limit="9.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1), N=241,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="2.02" upper_limit="2.25"/>
                    <measurement group_id="O2" value="2.44" lower_limit="2.23" upper_limit="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 29), N=241,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="26"/>
                    <measurement group_id="O2" value="7.09" lower_limit="5.29" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="1.94" upper_limit="2.33"/>
                    <measurement group_id="O2" value="3.91" lower_limit="3.36" upper_limit="4.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 29), N=240,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="15" upper_limit="21"/>
                    <measurement group_id="O2" value="9.52" lower_limit="7.21" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=238,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="1.97" upper_limit="2.25"/>
                    <measurement group_id="O2" value="2.69" lower_limit="2.42" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 29), N=238,91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.91" upper_limit="14"/>
                    <measurement group_id="O2" value="8.48" lower_limit="6.01" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
        <description>Number of subjects (2-10 years, 2-5 years and 6-10 years old subjects) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y, 12 months after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
        <time_frame>12 months post vaccination (Day 360)</time_frame>
        <population>Analysis was done on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-10 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-10 Years)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (2-5 Years)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS (2-5 Years)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O5">
            <title>MenACWY-CRM (6-10 Years)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O6">
            <title>MenACWY-PS (6-10 Years)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) With hSBA ≥ 1:4 After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
          <description>Number of subjects (2-10 years, 2-5 years and 6-10 years old subjects) with hSBA ≥ 1:4 directed against N. meningitidis serogroups A, C, W and Y, 12 months after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="134"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=253,238,119,114,134,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 360), N=253,238,119,114,134,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1), N=252,240,119,114,133,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="44"/>
                    <measurement group_id="O6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 360), N=252,240,119,114,133,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="95"/>
                    <measurement group_id="O6" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=249,237,119,113,130,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 360), N=249,237,119,113,130,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="108"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="126"/>
                    <measurement group_id="O6" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=250,239,118,113,132,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 360), N=250,239,118,113,132,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="114"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
        <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-10 years, 2-5 years and 6-10 years old), twelve months after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
        <time_frame>12 months post vaccination (Day 360)</time_frame>
        <population>Analysis was done on per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-10 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-10 Years Old)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (2-5 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS (2-5 Years Old)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O5">
            <title>MenACWY-CRM (6-10 Years Old)</title>
            <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O6">
            <title>MenACWY-PS (6-10 Years Old)</title>
            <description>Subjects received one dose of the licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>hSBA Geometric Mean Titer (GMT) in Subjects (2-10 Years, 2-5 Years and 6-10 Years Old) After Receiving Either MenACWY-CRM Vaccine or MenACWY-PS Vaccine</title>
          <description>hSBA GMT against N. meningitidis serogroups A, C, W, and Y, in subjects (2-10 years, 2-5 years and 6-10 years old), twelve months after receiving one dose of either MenACWY-CRM vaccine or MenACWY-PS vaccine.</description>
          <population>Analysis was done on per protocol population.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="119"/>
                <count group_id="O4" value="114"/>
                <count group_id="O5" value="134"/>
                <count group_id="O6" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A (Day 1), N=253,238,119,114,134,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" lower_limit="2.02" upper_limit="2.11"/>
                    <measurement group_id="O2" value="2.02" lower_limit="1.97" upper_limit="2.07"/>
                    <measurement group_id="O3" value="2.04" lower_limit="2" upper_limit="2.08"/>
                    <measurement group_id="O4" value="2" lower_limit="1.96" upper_limit="2.04"/>
                    <measurement group_id="O5" value="2.09" lower_limit="2" upper_limit="2.17"/>
                    <measurement group_id="O6" value="2.04" lower_limit="1.95" upper_limit="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A (Day 360), N=253,238,119114,134,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" lower_limit="3.39" upper_limit="4.44"/>
                    <measurement group_id="O2" value="3" lower_limit="2.61" upper_limit="3.44"/>
                    <measurement group_id="O3" value="3.15" lower_limit="2.73" upper_limit="3.64"/>
                    <measurement group_id="O4" value="2.49" lower_limit="2.15" upper_limit="2.89"/>
                    <measurement group_id="O5" value="4.66" lower_limit="3.75" upper_limit="5.8"/>
                    <measurement group_id="O6" value="3.55" lower_limit="2.83" upper_limit="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 1), N=252,240,119,114,133,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="2.73" upper_limit="3.39"/>
                    <measurement group_id="O2" value="3.43" lower_limit="3.07" upper_limit="3.84"/>
                    <measurement group_id="O3" value="2.77" lower_limit="2.47" upper_limit="3.12"/>
                    <measurement group_id="O4" value="2.38" lower_limit="2.11" upper_limit="2.69"/>
                    <measurement group_id="O5" value="3.3" lower_limit="2.79" upper_limit="3.9"/>
                    <measurement group_id="O6" value="4.77" lower_limit="4.01" upper_limit="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup C (Day 360), N=252,240,119,114,133,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8.64" upper_limit="13"/>
                    <measurement group_id="O2" value="9.02" lower_limit="7.23" upper_limit="11"/>
                    <measurement group_id="O3" value="7.53" lower_limit="5.93" upper_limit="9.55"/>
                    <measurement group_id="O4" value="4.71" lower_limit="3.69" upper_limit="6.01"/>
                    <measurement group_id="O5" value="15" lower_limit="11" upper_limit="21"/>
                    <measurement group_id="O6" value="16" lower_limit="12" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 1), N=249,237,119,113,130,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.62" upper_limit="6.55"/>
                    <measurement group_id="O2" value="5.38" lower_limit="4.5" upper_limit="6.44"/>
                    <measurement group_id="O3" value="4.4" lower_limit="3.52" upper_limit="5.51"/>
                    <measurement group_id="O4" value="3.43" lower_limit="2.73" upper_limit="4.32"/>
                    <measurement group_id="O5" value="6.75" lower_limit="5.23" upper_limit="8.7"/>
                    <measurement group_id="O6" value="8.1" lower_limit="6.25" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup W (Day 360), N=249,237,119,113,130,124</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="35" upper_limit="50"/>
                    <measurement group_id="O2" value="7.57" lower_limit="6.33" upper_limit="9.07"/>
                    <measurement group_id="O3" value="36" lower_limit="28" upper_limit="46"/>
                    <measurement group_id="O4" value="4.95" lower_limit="3.83" upper_limit="6.4"/>
                    <measurement group_id="O5" value="49" lower_limit="38" upper_limit="62"/>
                    <measurement group_id="O6" value="11" lower_limit="8.75" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 1), N=250,239,118,113,132,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" lower_limit="2.9" upper_limit="3.73"/>
                    <measurement group_id="O2" value="3.4" lower_limit="2.99" upper_limit="3.87"/>
                    <measurement group_id="O3" value="3.04" lower_limit="2.62" upper_limit="3.53"/>
                    <measurement group_id="O4" value="2.56" lower_limit="2.2" upper_limit="2.98"/>
                    <measurement group_id="O5" value="3.53" lower_limit="2.91" upper_limit="4.27"/>
                    <measurement group_id="O6" value="4.39" lower_limit="3.61" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup Y (Day 360), N=250,239,118,113,132,126</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="22" upper_limit="33"/>
                    <measurement group_id="O2" value="5.29" lower_limit="4.34" upper_limit="6.45"/>
                    <measurement group_id="O3" value="24" lower_limit="19" upper_limit="31"/>
                    <measurement group_id="O4" value="3.42" lower_limit="2.65" upper_limit="4.43"/>
                    <measurement group_id="O5" value="30" lower_limit="23" upper_limit="40"/>
                    <measurement group_id="O6" value="7.82" lower_limit="5.86" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Children Aged 2 to 10 Years</title>
        <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine compared to the safety and tolerability of a single dose of licensed MenACWY-PS vaccine when administered to healthy children 2 to 10 years of age.</description>
        <time_frame>Day 1 to 7 post vaccination</time_frame>
        <population>Analysis was done on safety population i.e. all randomized subjects who received a vaccination and who had follow up safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-5 Years Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-5 Years Old)</title>
            <description>Subjects received one dose of licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (6-10 Years Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS (6-10 Years Old)</title>
            <description>Subjects received one dose of licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Children Aged 2 to 10 Years</title>
          <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine compared to the safety and tolerability of a single dose of licensed MenACWY-PS vaccine when administered to healthy children 2 to 10 years of age.</description>
          <population>Analysis was done on safety population i.e. all randomized subjects who received a vaccination and who had follow up safety data.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits, N=145,150</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="NA"/>
                    <measurement group_id="O4" value="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="NA"/>
                    <measurement group_id="O4" value="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="NA"/>
                    <measurement group_id="O4" value="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="NA"/>
                    <measurement group_id="O4" value="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="NA"/>
                    <measurement group_id="O4" value="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills, N=156, 157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA"/>
                    <measurement group_id="O2" value="NA"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, N=156, 157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA"/>
                    <measurement group_id="O2" value="NA"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise, N=156, 157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA"/>
                    <measurement group_id="O2" value="NA"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia, N=156, 157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA"/>
                    <measurement group_id="O2" value="NA"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia, N=151,153,156,157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, N=151,153,156,157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home due to reactions, N=146,151,154,156</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analg./antipyr. med. used, N=150,152,157,157</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months</title>
        <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine when administered in healthy toddlers (12-15 months old), alone or concomitantly with PnC and when administered in healthy toddlers (16-23 months old), alone or concomitantly with DTaP.</description>
        <time_frame>Day 1 to 7 post vaccination</time_frame>
        <population>Analysis was done on safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (12-15 Months)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM + PnC (12-15 Months)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine concomitantly with PnC</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (16-23 Months)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-CRM + DTaP (16-23 Months)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine concomitantly with DTaP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months</title>
          <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine when administered in healthy toddlers (12-15 months old), alone or concomitantly with PnC and when administered in healthy toddlers (16-23 months old), alone or concomitantly with DTaP.</description>
          <population>Analysis was done on safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site reaction induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits, N=74,70,71,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent crying, N=74,70,71,72</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic/antipyretic medicine used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs) After Vaccination in Children Aged 2 to 10 Years</title>
        <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine compared to the safety and tolerability of a single dose of licensed MenACWY-PS vaccine when administered to healthy children 2 to 10 years of age.</description>
        <time_frame>Day 1- Day 360 (throughout the study)</time_frame>
        <population>Analysis was done on safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2-5 Years Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-PS (2-5 Years Old)</title>
            <description>Subjects received one dose of licensed MenACWY-PS vaccine</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (6-10 Years Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-PS (6-10 Years Old)</title>
            <description>Subjects received one dose of licensed MenACWY-PS vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events (AEs) After Vaccination in Children Aged 2 to 10 Years</title>
          <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine compared to the safety and tolerability of a single dose of licensed MenACWY-PS vaccine when administered to healthy children 2 to 10 years of age.</description>
          <population>Analysis was done on safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="157"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or probably related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months</title>
        <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine when administered in healthy toddlers (12-15 months old), alone or concomitantly with PnC and when administered in healthy toddlers (16-23 months old), alone or concomitantly with DTaP.</description>
        <time_frame>Day 1- Day 360 (Throughout the study)</time_frame>
        <population>Analysis was done on safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (12-15 Months Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM + PnC (12-15 Months Old)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine in concomitant with PnC</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (16-23 Months)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine</description>
          </group>
          <group group_id="O4">
            <title>MenACWY-CRM + DTaP (16-23 Months)</title>
            <description>Subjects received one dose of investigational MenACWY-CRM conjugate vaccine in concomitant with DTaP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Unsolicited Adverse Events After Vaccination in Toddlers Aged 12 to 23 Months</title>
          <description>Safety and tolerability of a single dose of MenACWY-CRM conjugate vaccine when administered in healthy toddlers (12-15 months old), alone or concomitantly with PnC and when administered in healthy toddlers (16-23 months old), alone or concomitantly with DTaP.</description>
          <population>Analysis was done on safety population.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="71"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly or probably related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to premature withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious Adverse Events (SAEs), AEs leading to premature withdrawal and any medically significant AEs were collected from Day 1 to 360</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MenACWY (2-5 Years Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="E2">
          <title>MenACWY-PS (2-5 Years Old)</title>
          <description>Subjects received one dose of the licensed MenACWY-polysaccharide vaccine.</description>
        </group>
        <group group_id="E3">
          <title>MenACWY (6-10 Years Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="E4">
          <title>MenACWY-PS (6-10 Years Old)</title>
          <description>Subjects received one dose of the licensed MenACWY-CRM polysaccharide vaccine.</description>
        </group>
        <group group_id="E5">
          <title>MenACWY (12-15 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="E6">
          <title>MenACWY-PnC (12-15 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine administered concomitantly with pneumococcal conjugate vaccine.</description>
        </group>
        <group group_id="E7">
          <title>MenACWY (16-23 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine.</description>
        </group>
        <group group_id="E8">
          <title>MenACWY+DTaP (16-23 Months Old)</title>
          <description>Subjects received one dose of the investigational MenACWY-CRM conjugate vaccine administered concomitantly with DTaP vaccine.</description>
        </group>
        <group group_id="E9">
          <title>MenACWY-PS (3-5 Years Old)</title>
          <description>Children aged 3 to 5 years receiving MenACWY-PS from the first part of the study (Menomune not licensed in US in children under 2 years of ages) served as controls for the 12-23-months-old part two toddlers.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>APPENDICITIS PERFORATED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>FEBRILE CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>BRONCHIAL HYPERREACTIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="61" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="62" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="59" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="40" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>TEETHING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>CRYING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INJECTION SITE INDURATION</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="22" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CROUP INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="25" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>EATING DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

